Takeda’s Position on Access to Medicines

Key Messages
At Takeda, accelerating patient access to medicines and vaccines is ingrained in our company values. We believe broadening access to our life-changing medicines and vaccines in underserved communities requires an integrated, sustainable approach that mobilizes collective efforts. By partnering with diverse stakeholders, we are actively addressing barriers to access and strengthening healthcare systems to improve lives worldwide.

Background
Despite major scientific breakthroughs in recent years, the WHO estimates that nearly 2 billion people globally lack access to essential medicines. While barriers to access exist around the world, those most acutely impacted are underserved communities in countries with evolving healthcare systems or limited access to resources. Barriers to access within, and between, populations range from the levels of capacity and resources needed to prevent, educate, and raise awareness within a community, to the specialized skills needed by healthcare to screen, diagnose and treat patients.

Takeda’s Approach
As a patient-focused, R&D-driven, global biopharmaceutical company, Takeda exists to create a better health for people and a brighter future for the world. Guided by values of Takeda-ism and brought to life through our decision-making framework of Patient-Trust-Reputation-Business, in that order, our Access to Medicines approach is central to our commitment to patients and is outlined in our corporate philosophy.

We are committed to broadening sustainable access to our life-changing medicines and vaccines where there is a high unmet medical need – particularly for patients in underserved communities.

We believe addressing the unmet healthcare needs of underserved communities requires an integrated, sustainable approach that mobilizes collective efforts.

Integrated
Takeda’s Access to Medicines approach is a cross-functional effort, integrated within our business strategy and across our operations to prioritize access from start to finish of a medicine’s development and delivery process. By embedding access commitments into our business strategy, from research & development to commercialization, we are actively addressing the barriers to access for patients to our life-changing medicines and vaccines.
**Sustainable**

At Takeda we believe that to meet the long-term needs of patients, access frameworks must be sustainable. We also recognize different contexts and barriers mean imposing a ‘one-size-fits-all’ approach is often ineffective. Our approach to delivering sustainable access to medicines initiatives includes:

- Ensuring uninterrupted, sufficient, and timely supply of products.
- Addressing healthcare infrastructure and capacity across the entire patient experience, from disease awareness, to diagnosis and management, to ongoing patient care and support.
- Treatment duration – taking into consideration the length of time a patient requires access to treatment, the resources required to deliver treatment for the appropriate duration and ongoing access to healthcare professional support.
- Safety and efficacy data to support use.
- Following pro-access IP arrangements and where possible, supporting voluntary licenses or offering licenses for low-cost access to our medicines – please see [here](#) for our full position on IP and [here](#) for pricing.
- Through the delivery of targeted, sustainable, and locally specific initiatives, we remain steadfast in our commitment to prioritize unmet patient needs through uninterrupted access to medicines and our world-class research and development (R&D) efforts, transformative therapies and a values-based approach to strengthening health care systems.

**Collaborative**

Takeda believes that mobilizing collective efforts across the public and private sector is critical to address the underlying barriers to access and strengthen in-country health systems, allowing for the sustainable and scalable implementation of access programs. This includes partnering with policymakers, governments, NGOs, industry peers, healthcare professionals, patient organizations and civil society, to support the sustainability of healthcare systems.

Broadening access to medicines and vaccines is not something we can do alone. By partnering with diverse stakeholders, we are actively addressing barriers to access and strengthening health systems to improve lives worldwide.

**Making an Impact: 3 Strategic imperatives**

*To deliver on our values-based approach to broaden access to our life-changing medicines and vaccines in a sustainable way, we focus on three strategic imperatives:*

1. Collaborate with partners to broaden patient access by strengthening healthcare systems.
2. Introduce and support innovative programs that address affordability barriers and enable access to medicines and vaccines. Including:
   - Tiered pricing
   - Takeda’s means-tested innovative Patient Assistance Programs
   - Value Based Healthcare models
3. Work with policy makers to broaden patient access our medicines and vaccines.
We measure our impact on the lives of patients in a consistent, transparent, and independent way to evaluate and hold ourselves and our partners accountable.

Designed by Duke University Innovations in Healthcare and Broadreach, our Access to Health Impact framework enables a consistent approach to measuring the impact of our access to medicines initiatives. Validated by leaders in the pharmaceutical industry, partners, academics and clinicians, our ambition is to create a multistakeholder Global Coalition for Access to Health that uses the framework as an industry-standard resource.

Our commitment to broadening and accelerating access is recognised by independent organisations and indices including the Access to Medicine Foundation and the Dow Jones Sustainability Index.

**Closing**

Our commitment to broadening patient access to our life-changing medicines and vaccines in underserved communities is ingrained in our corporate values, is integrated into our business model, and is improving lives worldwide by working with others to create and broaden sustainable access to medicines and vaccines.

March 2022